Record investment into local incubators

Private investment into old and new incubators reached a record high of $400 million in 2006 more than double the amount of $175m. invested the year before.

By SHARON WROBEL
March 5, 2007 07:03

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For a symbolic $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Don't show it again

Private investment into old and new incubators reached a record high of $400 million in 2006 more than double the amount of $175m. invested the year before. "In addition to their achievements, a great number of young and old incubators received approvals by the US Food & Drug Administration and thus many distribution agreements for the worldwide sale of their products were forged," Rina Pridor, director of the Technological Incubators Program at the Office of the Chief Scientist said Sunday. In light of the annual celebration of the Technological Incubators Program this Tuesday, the Office of the Chief Scientist has published the achievements of 11 graduated incubators. Among them are Sightline Technologies Ltd., which last year was acquired for $150m. by US medical technology company Stryker Corporation and specializes in the manufacturing and marketing of advanced endoscopic solutions for gastroenterological applications. Others mentioned were Capital Point Ltd., which went public on the Tel Aviv Stock Exchange and raised NIS 40m. Furthermore, Dentsply, the second largest dental devices company in the world, acquired Israel's Urident for $100m.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS